Methods of treatment and diagnosis of multiple myeloma progression
AssigneeMorehouse School of Medicine
InventorsJames W. LILLARD, JR., Olayinka ADEBAYO
Life of this patent
Estimating the term…
Loading patent…
AssigneeMorehouse School of Medicine
InventorsJames W. LILLARD, JR., Olayinka ADEBAYO
Estimating the term…
A method of treating multiple myeloma, comprising administering one or more agents increasing or inhibiting the expression or activity of one or more MM biomarkers to inhibit the progression of multiple myeloma, wherein the one or more MM biomarkers correspond to gene products from one or more of GABRA3, CTAG2, MAGEA6, SOHLH1, MAGEA1, AFAP1-AS1; CBX2, LINC00484, KIF7, TMSB15A, NEK2, NTRK1, CCND2, NES, PKP2, C1orf226, IFITM1, CDH23, AGRN, DHX58, and LINC02576. A method of diagnosing and treating multiple myeloma in a subject comprises, (a) measuring the level of one or more biomarkers in a sample; (b) comparing the level of the one or more biomarkers to a reference level of the one or more biomarkers; (c) making a diagnosis based on the result of the comparing step; and (d) treating the subject with one or more active agents where the subject is diagnosed with multiple myeloma.
A method of diagnosing and treating multiple myeloma (MM) in a subject comprising,
A method for determining disease progression or risk for metastasis in a subject with multiple myeloma, comprising the steps of:
A method for determining the efficacy of a treatment for multiple myeloma in a subject, comprising the steps of:
Dependencies are inferred from the claim text.